PDCD1 and neoplasm: To integrate multiple host– and tumour–specific variables at play, we used previously described systems biology– and machine learning –based techniques (Therapeutic Performance Mapping System, TPMS) [18] to model the mechanism of action of frontline treatment cabozantinib plus a PD1 inhibitor in mRCC.